- Home
- HEQ vs APLT Comparison
HEQ vs APLT Comparison
Compare HEQ & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEQ
- APLT
- Stock Information
- Founded
- HEQ 2011
- APLT 2016
- Country
- HEQ United States
- APLT United States
- Employees
- HEQ N/A
- APLT 37
- Industry
- HEQ Investment Managers
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- HEQ Finance
- APLT Health Care
- Exchange
- HEQ Nasdaq
- APLT Nasdaq
- Market Cap
- HEQ 132.3M
- APLT 128.0M
- IPO Year
- HEQ N/A
- APLT 2019
- Fundamental
- Price
- HEQ $10.42
- APLT $1.10
- Analyst Decision
- HEQ
- APLT Buy
- Analyst Count
- HEQ 0
- APLT 6
- Target Price
- HEQ N/A
- APLT $6.60
- AVG Volume (30 Days)
- HEQ 43.1K
- APLT 10.8M
- Earning Date
- HEQ 01-01-0001
- APLT 11-07-2024
- Dividend Yield
- HEQ 9.78%
- APLT N/A
- EPS Growth
- HEQ N/A
- APLT N/A
- EPS
- HEQ N/A
- APLT N/A
- Revenue
- HEQ N/A
- APLT N/A
- Revenue This Year
- HEQ N/A
- APLT N/A
- Revenue Next Year
- HEQ N/A
- APLT $5,117.00
- P/E Ratio
- HEQ N/A
- APLT N/A
- Revenue Growth
- HEQ N/A
- APLT N/A
- 52 Week Low
- HEQ $9.08
- APLT $1.03
- 52 Week High
- HEQ $11.84
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- HEQ 30.72
- APLT 17.64
- Support Level
- HEQ $10.90
- APLT $1.03
- Resistance Level
- HEQ $11.06
- APLT $1.37
- Average True Range (ATR)
- HEQ 0.10
- APLT 0.33
- MACD
- HEQ -0.07
- APLT -0.15
- Stochastic Oscillator
- HEQ 0.00
- APLT 0.75
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.